Combination Effect of Titrated Extract of Centella asiatica and Astaxanthin in a Mouse Model of Phthalic Anhydride-Induced Atopic Dermatitis
10.4168/aair.2019.11.4.548
- Author:
Ju Ho PARK
1
;
In Jun YEO
;
Jun Sung JANG
;
Ki Cheon KIM
;
Mi Hee PARK
;
Hee Pom LEE
;
Sang Bae HAN
;
Jin Tae HONG
Author Information
1. College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Korea. jinthong@chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
Astaxanthin;
atopic dermatitis;
inflammation;
titrated extract of Centella asiatica;
NF-κB
- MeSH:
Animals;
Blotting, Western;
Centella;
Dermatitis;
Dermatitis, Atopic;
Ear;
Enzyme-Linked Immunosorbent Assay;
Immunoglobulin E;
Immunoglobulins;
Inflammation;
Interleukin-6;
Interleukins;
Mice;
Nitric Oxide Synthase Type II;
Prevalence;
Skin;
Tumor Necrosis Factor-alpha
- From:Allergy, Asthma & Immunology Research
2019;11(4):548-559
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: In our previous study, we demonstrated that both titrated extract of Centella asiatica (TECA) and astaxanthin (AST) have anti-inflammatory effects in a 5% phthalic anhydride (PA) mouse model of atopic dermatitis (AD). The increasing prevalence of AD demands new therapeutic approaches for treating the disease. We investigated the therapeutic efficacy of the ointment form of TECA, AST and a TECA + AST combination in a mouse model of AD to see whether a combination of the reduced doses of 2 compounds could have a synergistic effect. METHODS: An AD-like lesion was induced by the topical application of 5% PA to the dorsal ear and back skin of an Hos:HR-1 mouse. After AD induction, TECA (0.5%), AST (0.5%) and the TECA (0.25%) + AST (0.25%) combination ointment (20 μg/cm2) were spread on the dorsum of the ear or back skin 3 times a week for 4 weeks. We evaluated dermatitis severity, histopathological changes and changes in protein expression by Western blotting for inducible nitric oxide synthase (iNOS), cyclocxygenase (COX)-2, and nuclear factor (NF)-κB activity. We also measured the concentrations of tumor necrosis factor (TNF)-α, interleukin (IL)-6 and immunoglobulin E (IgE) in the blood of AD mice by enzyme-linked immunosorbent assay (ELISA). RESULTS: PA-induced skin morphological changes and ear thickness were significantly reduced by TECA, AST and TECA + AST treatments, but these inhibiting effects were more pronounced in the TECA + AST treatment. TECA, AST and the TECA+AST reatments inhibited the expression of iNOS and COX-2; NF-κB activity; and the release of TNF-α, IL-6 and IgE. However, the TECA+AST treatment showed additive or synergistic effects on AD. CONCLUSIONS: Our results demonstrate that the combination of TECA and AST could be a promising therapeutic agent for AD by inhibiting NF-κB signaling.
